Vertebral Fractures Following Stereotactic Body Radiotherapy for Spine Oligometastases: A Multi-institutional Analysis of Patient Outcomes. Issue 7 (July 2020)

• Record Type: Journal Article
• Authors: Abbouchie, H.; Chao, M.; Tacey, M.; Joon, D.L.; Ho, H.; Guerrieri, M.; Ng, M.; Foroudi, F.
• Is Part Of: Clinical oncology. Volume 32:Issue 7(2020)
• Page Start: 433
• Page End: 441
• Publication Date: 2020-07
• Subjects: Local control -- Overall survival -- Spinal Instability Neoplastic Score -- Spine metastases -- Stereotactic body radiotherapy -- Vertebral compression fractures; Oncology -- Periodicals; Tumors -- Periodicals; Cancer -- Treatment -- Periodicals; Radiotherapy -- Periodicals; Neoplasms -- Periodicals; Cancer -- Radiotherapy; Cancer -- Treatment; Oncology; Medical radiology; Radiotherapy; Tumors; Electronic journals; Periodicals; 616.994
• DOI: 10.1016/j.clon.2020.02.030
• Languages: English
• ISSNs: 0936-6555

Abstract

Abstract: Aims: Stereotactic body radiotherapy (SBRT) is a locally ablative therapy used for the treatment of patients with spine metastases. However, it is associated with higher rates of vertebral compression fractures (VCF) than conventionally fractionated palliative radiotherapy. The purpose of this study was to determine the rate of VCF following spine SBRT and to identify the risk factors associated with this outcome. Materials and methods: We retrospectively reviewed patients treated at two Australian institutions from January 2015 to March 2019. Descriptive statistics were used to assess patient, tumour and treatment factors. The Log-rank test and Cox proportional hazards model were applied in univariate and multivariable analyses to identify factors associated with VCF, local control and overall survival. Results: We evaluated 113 spinal segments from 84 patients, with a median follow-up time of 11.9 months. The median dose and fractionation utilised was 30 Gy in three fractions (67.3%), with a single-fraction rate of 0.9%. The median Spinal Instability Neoplastic Score (SINS) of the lesions was 4/18, with most (84.1%) being SINS stable, scoring between 0 and 6. Five VCFs were observed (three progression of pre-existing fractures and two de novo ), a cumulative VCF risk of 4.4%. Four of five fractures occurred within the first year after treatment, with a median time to VCF of 9.2 months. A pre-existing VCF ( P = 0.011) was associated with subsequent fracture on multivariable analysis, whereas all VCF segments displayed lytic disease appearance. All fractures were managed conservatively with analgesia, without requirement for subsequent surgical intervention. Conclusion: SBRT to spine metastases is safe with respect to VCF, with rates around the lower limit observed in similar studies. Knowledge of factors that predispose to post-treatment fracture, such as pre-existing compression, lytic vertebral disease and SINS >6 will aid in the counselling and selection of patients for this therapy. Highlights: 30 Gy delivered in 3 fractions is an appropriate regimen for spine metastases. Spine stereotactic radiotherapy resulted in a fracture rate of 4.4%. These were managed conservatively with no surgical requirement. Pre-existing compression, mechanical instability and lytic disease were predictive. Rates of local control at 1 and 2 years were 78.8% and 72.4%, respectively.